Sign in
CompletedNo phase

Clareon PanOptix Pro vs. Clareon PanOptix - Study B

Key facts

Who runs it
Alcon Research
Where
Bloomfield Hills, Charleston, Cincinnati, Houston, Kansas City, Nashville, Salt Lake City, and Torrance, United StatesSee the 8 sites
Trial code
Status
Completed
People taking part
71 people enrolled
Started
18 Jun 2024
Ended
30 Apr 2025
Type of study
Interventional, 2 groups
Treatments tested
  • CPO Pro IOL
  • CPO IOL
  • Cataract Surgery
Record updated
2 June 2026

Who can take part

Age
22 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Understand and sign an ethics committee-approved informed consent form
  • Willing and able to attend all scheduled study visits as required by the protocol
  • Planned cataract surgery (both eyes)
  • Preoperative corneal astigmatism less that 1.00 diopter in each eye
  • Other protocol-defined inclusion criteria may apply

Who cannot take part

  • Ocular conditions as specified in the protocol
  • Women of childbearing potential if currently pregnant, intend to become pregnant during the study, or are breastfeeding
  • Subjects who desire monovision correction
  • Other protocol-defined exclusion criteria may apply

Where in United States

  • Grosinger, Spigelman & Grey Eye Surgeons, P.C.Bloomfield Hills, United States
  • Carolina Eye Care PhysiciansCharleston, United States
  • Cincinnati Eye InstituteCincinnati, United States
  • Houston Eye AssociatesHouston, United States
  • Moyes Eye CenterKansas City, United States
  • Vision for LifeNashville, United States
  • The Eye Institute of UtahSalt Lake City, United States
  • Wolstan & Goldberg Eye AssociatesTorrance, United States

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™ PanOptix™ Trifocal IOL.

The 2 groups in the trial

  • CPO Pro IOLTreatment being tested

    CPO Pro IOL implanted in the first eye, as randomized. The fellow eye will receive CPO IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.

    Treatment: CPO Pro IOL, CPO IOL, and Cataract Surgery

  • CPO IOLTreatment being tested

    CPO IOL implanted in the first eye, as randomized. The fellow eye will receive CPO Pro IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.

    Treatment: CPO Pro IOL, CPO IOL, and Cataract Surgery

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Contralateral Study of Clareon PanOptix Pro vs. Clareon PanOptix
Record updated
2 June 2026